Catalyst Wire Dossier Catalyst Wire Dossier

Syn3

SCH 209702
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Syn3, covering 2016-11-28 to 2016-11-28. Get the full timeline:

Most recent: Clinical Trial Update: 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer [Phase 1]

See pricing